Trial Profile
Ciclesonide for the Treatment of Airway Hyperresponsiveness. The Mannitol-Asthma-Ciclesonide Study (MACS). A Double-Blind, Randomized, Parallel Group Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ciclesonide (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms MACS
- Sponsors AstraZeneca; Takeda Pharmaceuticals International GmbH
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 04 May 2012 Company added in association field as reported by ClinicalTrials.gov.
- 04 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.